Combined with the above results, we believe that DARS/GDI2/P4HA2 / TRUB1 may be involved in these processes to affect the occurrence and development of GBM disease, which is also consistent with our Drug sensitivity analysis results. This evidence concerns the gene GDI2 and glioblastoma.